Codexis to Report First Quarter 2023 Financial Results on May 4
Codexis (NASDAQ: CDXS) announced it will release its financial results for Q1 2023 on May 4, 2023, after market closure. The company will not hold a conference call following this release. Codexis specializes in enzyme engineering, utilizing its CodeEvolver® technology platform to develop high-performance enzymes for various applications, including pharmaceuticals and biotherapeutics. Their technology aims to enhance manufacturing efficiency, reduce energy consumption, and improve therapeutic efficacy. The company's innovations address challenges in small molecule production, nucleic acid synthesis, and genomic sequencing.
- Codexis' enzyme engineering focus aligns with increasing demand for efficient pharmaceutical manufacturing solutions.
- Proprietary CodeEvolver® technology enhances enzyme performance, potentially driving future growth.
- No conference call will be held post-earnings, limiting investor engagement.
REDWOOD CITY, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2023 on Thursday, May 4, 2023, following the close of market. The Company will not be conducting a conference call in conjunction with this financial results release.
About Codexis
Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing, nucleic acid synthesis and genomic sequencing, and – as biotherapeutic candidates – they have the potential to treat challenging diseases. Codexis’ unique enzymes drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing, greater sensitivity in genomic and diagnostic applications and potentially more efficacious therapeutics. For more information, visit www.codexis.com.
For More Information
Investor Contact
Carrie McKim
(336) 608-9706
ir@codexis.com
Media Contact
Lauren Musto
(781) 572-1147
media@codexis.com
FAQ
When will Codexis report its Q1 2023 financial results?
What is the significance of Codexis' CodeEvolver® technology?
Will Codexis hold a conference call after the earnings release?
How does Codexis address pharmaceutical manufacturing challenges?
